Publications by authors named "Jon C Jones"

Claim this Profile
D
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies.
Michael Wichroski, Si-Qi Liu, Lauren M Zasadil, Joseph L Benci, Patrick C Gedeon, Jon C Jones

Cancer Immunol Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Jim S Qin, Timothy G Johnstone, Alex Baturevych, Ronald J Hause, Seamus P Ragan, Jon C Jones

J Immunother· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide.
Melissa Works, Neha Soni, Collin Hauskins, Catherine Sierra, Alex Baturevych, Jon C Jones

Mol Cancer Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.
Shyril O'Steen, Melissa L Comstock, Johnnie J Orozco, Donald K Hamlin, D Scott Wilbur, Jon C Jones

Blood· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.
Brian W Miller, Sofia H L Frost, Shani L Frayo, Aimee L Kenoyer, Erlinda Santos, Jon C Jones

Med Phys· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.
Damian J Green, Mazyar Shadman, Jon C Jones, Shani L Frayo, Aimee L Kenoyer

Blood· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
Robert E Miller, Jon C Jones, Mark Tometsko, Michelle L Blake, William C Dougall

J Thorac Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RANK expression on breast cancer cells promotes skeletal metastasis.
Michelle L Blake, Mark Tometsko, Robert Miller, Jon C Jones, William C Dougall

Clin Exp Metastasis· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.
Damian J Green, Nural N Orgun, Jon C Jones, Mark D Hylarides, John M Pagel

Cancer Res· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of low-molecular-weight heparin to decrease mortality in mice after intracardiac injection of tumor cells.
Kim L Stocking, Jon C Jones, Nancy E Everds, Bernard S Buetow, Martine P Roudier

Comp Med· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Allison P Armstrong, Robert E Miller, Jon C Jones, Jian Zhang, Evan T Keller

Prostate· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis